Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22417061 | 0.92 | CARM1 (0.59) | KLKB1CARM1 | |
| SCHEMBL20579755 | 0.91 | KLKB1 (0.53) | KLKB1CARM1 | |
| SCHEMBL21919181 | 0.91 | CARM1 (0.60) | KLKB1CARM1 | |
| SCHEMBL22416926 | 0.90 | CARM1 (0.73) | KLKB1CARM1 | |
| SCHEMBL7478179 | 0.89 | KLKB1 (0.55) | KLKB1CARM1 | |
| SCHEMBL22967845 | 0.88 | KLKB1 (0.54) | KLKB1CARM1 | |
| SCHEMBL21100670 | 0.87 | KLKB1 (0.56) | KLKB1CARM1 | |
| SCHEMBL22417105 | 0.87 | CARM1 (0.61) | KLKB1CARM1 | |
| SCHEMBL5471345 | 0.87 | CARM1 (0.63) | KLKB1CARM1 | |
| SCHEMBL5476608 | 0.87 | CARM1 (0.63) | KLKB1CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116375648-A | Preparation method of Bei Luosi intermediate | 苏州农平科技发展有限公司 | 2023-07-04 | — | — | CN | claimed |
| US-12590069-B2 | Crystalline salts of a plasma kallikrein inhibitor | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12590068-B2 | Crystalline salts of a plasma kallikrein inhibitor | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12552750-B2 | Crystalline salts of a plasma kallikrein inhibitor | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12545647-B2 | Crystalline salts of a plasma kallikrein inhibitor | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12545646-B2 | Crystalline salts of a plasma kallikrein inhibitor | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12545645-B2 | Crystalline salts of a plasma kallikrein inhibitor | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250388547-A1 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-12-25 | — | — | US | disclosed |
| US-20250388546-A1 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-12-25 | — | — | US | disclosed |
| US-20250388549-A1 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-12-25 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
| EP-1603562-A4 | SULFONYL-AMIDINO CONTAINING AND TETRAHYDROPYRIMIDINO CONTAINING COMPOUNDS AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-10-22 | — | — | EP | disclosed |
| US-7122557-B2 | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1603562-A2 | SULFONYL-AMIDINO CONTAINING AND TETRAHYDROPYRIMIDINO CONTAINING COMPOUNDS AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050203127-A1 | 2-(Phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses | MERCK PATENT GMBH (DE) | 2005-09-15 | — | — | US | disclosed |
| US-20040209863-A1 | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-21 | — | — | US | disclosed |
| WO-2004083174-A2 | SULFONYL-AMIDINO CONTAINING AND TETRAHYDROPYRIMIDINO CONTAINING COMPOUNDS AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004002477-A1 | 2-(PHENYL)-2H-PYRAZOLE-3-CARBOXYLIC ACID-N-4-(THIOXO-HETEROCYCLYL)-PHENYL-AMIDE DERIVATIVES AND CORRESPONDING IMINO-HETEROCYCLYL DERIVATIVES AND RELATES COMPOUNDS FOR USE AS INHIBITORS OF THE COAGULATION FACTORS XA AND/OR VIIA FOR TREATING THROMBOSES | MERCK PATENT GMBH (DE) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545645-B2 | Crystalline salts of a plasma kallikrein inhibitor | KLKB1, KLK1, KLK2 | KLKB1 1/4885CARM1 3959/4885 |
| US-12545646-B2 | Crystalline salts of a plasma kallikrein inhibitor | KLKB1, KLK1, KLK2 | KLKB1 1/4885CARM1 3801/4885 |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | CARM1, PRMT1, PRMT3 | KLKB1 4560/4885CARM1 1/4885 |
| US-20250388547-A1 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | KLKB1, KLK1, KLK2 | KLKB1 1/4885CARM1 3801/4885 |
| US-20250388549-A1 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | KLKB1, KLK1, KLK2 | KLKB1 1/4885CARM1 3688/4885 |
| US-12590069-B2 | Crystalline salts of a plasma kallikrein inhibitor | KLKB1, KLK2, KLK1 | KLKB1 1/4885CARM1 3401/4885 |
| US-20040209863-A1 | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors | TFPI, SPINT2, TMPRSS4 | KLKB1 236/4885CARM1 2533/4885 |
| US-12552750-B2 | Crystalline salts of a plasma kallikrein inhibitor | KLKB1, F2, KLK1 | KLKB1 1/4885CARM1 3418/4885 |
| US-12590068-B2 | Crystalline salts of a plasma kallikrein inhibitor | KLKB1, KLK1, KLK2 | KLKB1 1/4885CARM1 3688/4885 |
| US-20250388546-A1 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | KLKB1, KLK1, KLK2 | KLKB1 1/4885CARM1 3959/4885 |
| US-12545647-B2 | Crystalline salts of a plasma kallikrein inhibitor | KLKB1, KLK1, KLK2 | KLKB1 1/4885CARM1 3576/4885 |
| US-20050203127-A1 | 2-(Phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses | F11, F12, F2 | KLKB1 861/4885CARM1 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.